CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

Stan Polovets highlights the Genesis Prize's role in celebrating Jewish excellence and driving global impact through ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert Bourla ... overseen by Dr. Chris Boshoff ...

Pfizer CEO Dr Albert Bourla presided over an exceptional Q3 amid financial decline and pressure from investor Starboard Value. Credit: Ververidis Vasilis / Shutterstock. Pfizer is cutting costs and ...

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...